Five-Year Survival Outcomes After Carbon-Ion Radiotherapy for Operable Stage I NSCLC: A Japanese National Registry Study (J-CROS-LUNG)-Reference-Cited by-同舟云学术

Five-Year Survival Outcomes After Carbon-Ion Radiotherapy for Operable Stage I NSCLC: A Japanese National Registry Study (J-CROS-LUNG)

Published:2023-11 Issue: Volume: Page:
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Kubo Nobuteru^ORCID,Suefuji Hiroaki,Nakajima Mio,Tokumaru Sunao,Okano Naoko,Yoshida Daisaku,Suzuki Osamu,Ishikawa Hitoshi,Satouchi Miyako,Nakayama Haruhiko,Shimizu Kimihiro,Shioyama Yoshiyuki

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference24 articles.

1. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials;Chang;Lancet Oncol,2015

2. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG0403;Nagata;Int J Radiat Oncol Biol Phys,2015

3. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery;Chang;Lancet Oncol,2021

4. Particle radiotherapy with carbon ion beams;Ohno;EPMA J,2013

5. Comparison of oncologic outcomes between carbon ion radiotherapy and stereotactic body radiotherapy for early-stage non-small cell lung cancer;Miyasaka;Cancers (Basel),2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry;Radiotherapy and Oncology;2024-09

2. Accurate Prognostic Factor for Carbon-Ion Radiotherapy in Operable Stage I NSCLC;Journal of Thoracic Oncology;2024-08

3. Survival and Prognosis After Carbon-Ion Radiotherapy in Patients With NSCLC;Journal of Thoracic Oncology;2024-03